Get the Stockscreener App
26.29
0.83%
-0.22
After Hours:
26.30
0.01
+0.04%
Janux Therapeutics Inc stock is traded at $26.29, with a volume of 1.12M.
It is down -0.83% in the last 24 hours and up +9.31% over the past month.
Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. Its proprietary technology has enabled the development of two distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr). The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.
See More
Previous Close:
$26.51
Open:
$26.39
24h Volume:
1.12M
Relative Volume:
1.39
Market Cap:
$1.58B
Revenue:
$439.00K
Net Income/Loss:
$-105.64M
P/E Ratio:
-14.61
EPS:
-1.8
Net Cash Flow:
$-60.70M
1W Performance:
+15.51%
1M Performance:
+9.31%
6M Performance:
-8.72%
1Y Performance:
-46.94%
1-Day Range:
$25.18
$26.62
1-Week Range:
$22.23
$26.73
52-Week Range:
$21.73
$71.71
Janux Therapeutics Inc Stock (JANX) Company Profile
Name
Janux Therapeutics Inc
Sector
Industry
Phone
(858) 751-4493
Address
10955 VISTA SORRENTO PARKWAY, SAN DIEGO
Compare JANX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
JANX
Janux Therapeutics Inc
|
26.29 | 1.59B | 439.00K | -105.64M | -60.70M | -1.80 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.37 | 104.55B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
464.95 | 60.36B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
557.73 | 59.84B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
799.56 | 49.07B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
327.03 | 35.16B | 4.56B | -176.77M | 225.30M | -1.7177 |
Janux Therapeutics Inc Stock (JANX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-17-25 | Initiated | Barclays | Overweight |
| Sep-10-25 | Initiated | Stifel | Buy |
| Sep-10-25 | Initiated | Truist | Buy |
| Sep-04-25 | Initiated | Guggenheim | Buy |
| Aug-19-25 | Initiated | Piper Sandler | Overweight |
| Jul-11-25 | Initiated | Raymond James | Outperform |
| Dec-03-24 | Reiterated | BTIG Research | Buy |
| Dec-03-24 | Reiterated | H.C. Wainwright | Buy |
| Nov-22-24 | Initiated | Leerink Partners | Outperform |
| Oct-24-24 | Initiated | UBS | Buy |
| Sep-06-24 | Initiated | Stifel | Buy |
| May-30-24 | Initiated | Scotiabank | Sector Perform |
| Mar-21-24 | Initiated | BTIG Research | Buy |
| Mar-20-24 | Initiated | Cantor Fitzgerald | Overweight |
| Apr-06-23 | Initiated | Wedbush | Outperform |
| Nov-14-22 | Initiated | William Blair | Outperform |
View All
Janux Therapeutics Inc Stock (JANX) Latest News
Real time alert setup for Janux Therapeutics Inc. performanceProduct Launch & Fast Entry Momentum Alerts - newser.com
Can Janux Therapeutics Inc. stock surprise with earnings upsideWeekly Profit Recap & Smart Allocation Stock Tips - newser.com
Is Janux Therapeutics Inc. stock attractive for income investorsExit Point & AI Powered Buy/Sell Recommendations - newser.com
Why Janux Therapeutics (JANX) Is Up 10.5% After Pipeline Progress Fuels Optimism for Prostate Cancer Therapies - Yahoo Finance
Janux Therapeutics (JANX) Surges 6.8%: Is This an Indication of Further Gains? - Yahoo Finance
Trend analysis for Janux Therapeutics Inc. this weekPortfolio Gains Report & Daily Growth Stock Investment Tips - newser.com
Can trapped investors hope for a rebound in Janux Therapeutics Inc.Portfolio Update Report & Weekly Setup with ROI Potential - newser.com
Is Janux Therapeutics Inc. stock poised for growthQuarterly Growth Report & Free Expert Verified Stock Movement Alerts - newser.com
Stoke Therapeutics (STOK) Surges 11.7%: Is This an Indication of Further Gains? - Yahoo Finance
What drives Janux Therapeutics Inc stock priceEarnings Per Share Trends & Rapid Portfolio Gain - earlytimes.in
Weiss Ratings Reaffirms Sell (D-) Rating for Janux Therapeutics (NASDAQ:JANX) - MarketBeat
Visual trend scoring systems applied to Janux Therapeutics Inc.Market Movement Recap & Accurate Entry and Exit Point Alerts - newser.com
How hedge fund analytics apply to Janux Therapeutics Inc. stockWeekly Trade Review & Capital Protection Trading Alerts - newser.com
Will a bounce in Janux Therapeutics Inc. offer an exitMarket Movement Recap & AI Enhanced Trading Signals - newser.com
How geopolitical tensions affect Janux Therapeutics Inc. stock2025 Momentum Check & Risk Controlled Stock Pick Alerts - newser.com
Janux Therapeutics Inc. recovery potential after sell offDollar Strength & Real-Time Volume Surge Alerts - newser.com
Leading vs lagging indicators on Janux Therapeutics Inc. performanceJuly 2025 Outlook & Community Supported Trade Ideas - newser.com
Janux Therapeutics Inc (JANX) Gets a Buy from Bank of America Securities - The Globe and Mail
BofA Securities Maintains Janux Therapeutics(JANX.US) With Buy Rating - 富途牛牛
What earnings revisions data tells us about Janux Therapeutics Inc.Recession Risk & Daily Profit Maximizing Tips - newser.com
Using data tools to time your Janux Therapeutics Inc. exitWeekly Trend Summary & High Accuracy Trade Signal Alerts - newser.com
Published on: 2025-10-03 01:15:11 - newser.com
Janux Therapeutics, Inc. (NASDAQ:JANX) Receives $78.31 Average PT from Brokerages - Defense World
Will Q4 Earnings Be a Catalyst for Jash Engineering LimitedDay Trading Setups & Affordable Investment Tips - earlytimes.in
Published on: 2025-09-29 03:27:23 - newser.com
Janux Therapeutics, Inc. (NASDAQ:JANX) Given Average Rating of "Buy" by Analysts - MarketBeat
Published on: 2025-09-27 15:26:00 - newser.com
What analysts say about Janux Therapeutics Inc stockBull Market Opportunities & Outstanding Trading Tips - earlytimes.in
Laser Photonics Corporation Stock Analysis and Forecast - Early Times
Janux Therapeutics Inc Stock (JANX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Janux Therapeutics Inc Stock (JANX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Meyer Andrew Hollman | Chief Business Officer |
May 01 '25 |
Sale |
32.03 |
3,333 |
106,745 |
82,139 |
1.11%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):